What is being reported

For suspected side effects being reported for medicines and vaccines, the MHRA publishes Yellow card data which can be accessed below.

The MHRA have implemented a new enhanced format of data visualisations. This enables us to provide improvements to accessibility whilst allowing access to more data than has been published previously. The initial phase of this development involved the provision of COVID-19 vaccine data. We are now in the next phase which now includes vaccination data and updated medicines interactive Drug Analysis Profiles (iDAPs).

Yellow Card interactive Drug Analysis Profiles (iDAPs)

Medicines are listed alphabetically by the name of the substance or combination of substances, not by the brand name. To find the name of the active substance in your medicine or vaccine, look at the patient information leaflet that was supplied with it. You can find patient information leaflets here.

Each iDAP contains a complete listing of all suspected adverse reactions that have been reported to the MHRA via the Yellow Card scheme. This includes all reports received from healthcare professionals, members of the public, and pharmaceutical companies.

The iDAP provided on this website are regularly updated. Please be aware, however, that if you have reported a suspected adverse drug reaction it may not immediately appear on this website. There is a time delay of around one month from receipt of a report to it appearing in the summary.

When reviewing the data within a iDAP it is important to do so in the context of the essential guidance at the bottom of the report to ensure that you do not misinterpret the data.

Reports on suspected side effects to COVID-19 vaccines is now part of the routine iDAP publication. If you are looking for data published during the COVID-19 pandemic, including historic reporting formats, please visit our legacy COVID-19 Vaccine iDAP page.

Release Notes

The MHRA have curated release notes regarding our new iDAP publications. These outline new features, changes, and upcoming improvements. Please find our iDAP release notes here.

Questions & comments

During their development iDAPs have been extensively tested with a variety of stakeholders, nevertheless if you have any questions or comments about how they should be used/ interpreted or if the substance you are interested in is not currently available, please do not hesitate to contact us.